Navigation Links
Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
Date:5/25/2011

onths.

Final results were also presented from the completed 28-day main portion of study 203. At the highest lesinurad dose tested in this study, patients achieved a 30 percent mean reduction in sUA levels after 4 weeks, compared to a 3 percent mean increase on allopurinol plus placebo (p< 0.0001).  This resulted in a response rate of 79 percent for the 600 mg dose (p< 0.0001) using the more rigorous "intent-to-treat" (ITT) analysis and 87 percent using a "last observation carried forward" (LOCF) analysis. As a result, the number of patients taking the combination who achieved the medically recommended target of below 6 mg/dL was more than three times the number of patients who achieved the target on allopurinol alone.

The combination of lesinurad and allopurinol was generally well tolerated in the main 28-day dosing period and has been well tolerated in the ongoing extension period. Adverse events were infrequent, not dose related and comparable between the groups receiving lesinurad and placebo.

Preclinical Data Presented

The Company also presented data from a completed preclinical study evaluating lesinurad's effect on the hyperuricemia caused by the commonly used diuretic, hydrochlorothiazide. Hypertension is prevalent in gout patients and they are often treated with anti-hypertensive agents such as thiazide diuretics.  These agents have for some time been known to reduce uric acid excretion from the kidney, and thus increase sUA levels, which can exacerbate the condition of gout patients. The reduction in uric acid excretion by these agents is believed to be due to activation of a uric acid transporter in the kidney known as OAT4.  Results from a completed preclinical study were presented at EULAR showing that lesinurad is an active inhibitor of the OAT4 transporter. This secondary activity may significantly offset the sUA-increasing effects of thiazide diuretics, thereby achieving a second
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... NEW YORK , August 4, 2015 /PRNewswire/ ... new research report with market overview, trends, DRO ... analysis, recent developments, competitive scenario and top competitor ... of Abuse Testing Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) , Explore full reports ...
(Date:8/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ) has ... by Application (Household & Personal Care, Pharmaceutical, Oilfield, Agrochemicals, ... 2019" report to their offering. ... $5,124.9 million in 2014 and is projected to grow ... 2019. The data mentioned in the report is based ...
(Date:8/4/2015)... Aug. 4, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... the development and commercialization of targeted antiviral therapies, ... Officer, will present live at VirtualInvestorConferences.com on August ... 2015 TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... interactive online event where investors are invited to ...
Breaking Medicine Technology:Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3
(Date:8/4/2015)... ... August 04, 2015 , ... Statement by Paul Gionfriddo, President ... of the Mental Health Reform Act of 2015 by Senators Bill Cassidy ... reform a reality in America. , “This legislation and H.R. 2646 ...
(Date:8/4/2015)... ... 2015 , ... assistPoint Partners, LLC is proud to ... assistance programs. Through a secure web portal, assistPoint connects Life Sciences, Patients and ... cloud-based application and workflow solution. This provides cancer center patient advocates, financial counselors ...
(Date:8/4/2015)... ... August 04, 2015 , ... Healthy Origins® Cognizin® Citicoline is ... trademark for Citicoline, a nutrient that supports memory function and healthly cognition.* , ... more of a semi-solid composition. Vegetarian capsules are also natural, non-toxic and ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s hard ... Medical & Day Spa in Santa Barbara, CA is offering the solution by ... that permanently eliminates sweat and odor glands in the underarms. This simple and ...
(Date:8/4/2015)... ... 04, 2015 , ... Recent studies in the ... in binge drinking among certain populations and specific locations. Researchers, who ... examine trends and evidence to help facilitate health care treatment to meet current ...
Breaking Medicine News(10 mins):Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 3Health News:assistPoint.com Web Site Launched 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3
... protects against endpoint threats and data leakage. , ... ... http://www.jcl.com/content/?rpLeadsourceId=7002 [John C. Lincoln Health Network __title__ John ... its 3,500 employees and 1,400 affiliated physicians with access to ...
... shareholder at law firm Anapol, Schwartz, Weiss, Cohan, Feldman and ... American Association for Justice,s (AAJ) executive committee at the organization,s ... ... Philadelphia (PRWEB) August 20, 2008 -- http://www.anapolschwartz.com/attorneys/sol_weiss.shtml?ID=toplintrack20081111 ...
... ev3 Inc. (Nasdaq:,EVVV) today announced that Pat Spangler, chief ... to present at the Morgan,Stanley Global Healthcare Unplugged Conference ... at the Grand Hyatt New York located at 109 ... York., To access the webcast, go to the ...
... Opens Practice Offering Enhanced Customer Service ... ... Aug. 19 ModernMed, http://www.ModernMed.com, announced its partnership with ... ,to provide patients with primary care focused on prevention and ...
... Harvest --,The Nation,s Food Bank Network is prepared to ... food banks in Florida that serve,people affected by Tropical ... country so that they will be,readily accessible and quickly ... Tropical Storm Fay headed to landfall, America,s Second Harvest,began ...
... formation, delayed onset of lung inflammation ... The use of silver-coated endotracheal tubes reduced ... on ventilators, a U.S. study found. ... hospital stays, increased costs, and infection with ...
Cached Medicine News:Health News:Lumension Security Debuts New Customer Testimonial Video 2Health News:Anapol Schwartz Attorney Named to Executive Committee of American Association for Justice 2Health News:ModernMed Announces Partnership With Dr. Neil J. Sapin, M.D. 2Health News:Silver-Coated Ventilator Tubes Cut Risk of Pneumonia 2
... is a powerful automated system capable of ... from 6 user-programmable test protocols to begin ... Any tests not included in the comprehensive ... handled using the Doppler, PVR and PPG ...
... The Nicolet VersaLab is ... line-operated Doppler system for ... vasculature. Crisp, clear Doppler ... with a display and ...
The CD Horizon M8 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
Silhouette is easy to use with uncompromised biomechanics and is the most refined posterior fixation system....
Medicine Products: